Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4882MR)

This product GTTS-WQ4882MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4882MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11409MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ5990MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ4604MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ11797MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ6146MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ14143MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ5757MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ402MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW